Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Teleflex Incorporated
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
- Medical Devices
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Surgical Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Arrow International
- Eon Surgical Ltd
- Hotspur Technologies
- Essential Medical, Inc.
- Hudson Respiratory Care, Inc.
- LMA International N.V.
- NeoTract, Inc.
- Nostix, LLC
- Pyng Medical Corporation
- Semprus BioSciences
- Standard Bariatrics, Inc.
- Ultimate Medical
- Vascular Solutions
- Vasonova Inc.
- Vidacare Corporation
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.